Last reviewed · How we verify
Adjuvant chemotherapy for experimental group
Adjuvant chemotherapy for experimental group is a Small molecule drug developed by Chinese Academy of Medical Sciences. It is currently in Phase 3 development for Adjuvant treatment in experimental oncology trial (specific cancer type not specified).
Adjuvant chemotherapy uses cytotoxic drugs administered after primary treatment to eliminate residual cancer cells and reduce recurrence risk.
Adjuvant chemotherapy uses cytotoxic drugs administered after primary treatment to eliminate residual cancer cells and reduce recurrence risk. Used for Adjuvant treatment in experimental oncology trial (specific cancer type not specified).
At a glance
| Generic name | Adjuvant chemotherapy for experimental group |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Adjuvant chemotherapy is a treatment strategy rather than a single drug, involving the use of chemotherapeutic agents (such as alkylating agents, platinum compounds, or antimetabolites) given following surgery or primary therapy. The goal is to target micrometastatic disease and improve overall survival by reducing the likelihood of cancer recurrence. The specific mechanism depends on the chemotherapy regimen selected for the experimental group.
Approved indications
- Adjuvant treatment in experimental oncology trial (specific cancer type not specified)
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Fatigue
- Peripheral neuropathy
Key clinical trials
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) (PHASE3)
- Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX (PHASE2, PHASE3)
- Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery (PHASE2)
- Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer (PHASE3)
- Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.
- Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (NA)
- Newly Diagnosed Glioblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvant chemotherapy for experimental group CI brief — competitive landscape report
- Adjuvant chemotherapy for experimental group updates RSS · CI watch RSS
- Chinese Academy of Medical Sciences portfolio CI
Frequently asked questions about Adjuvant chemotherapy for experimental group
What is Adjuvant chemotherapy for experimental group?
How does Adjuvant chemotherapy for experimental group work?
What is Adjuvant chemotherapy for experimental group used for?
Who makes Adjuvant chemotherapy for experimental group?
What development phase is Adjuvant chemotherapy for experimental group in?
What are the side effects of Adjuvant chemotherapy for experimental group?
Related
- Manufacturer: Chinese Academy of Medical Sciences — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment in experimental oncology trial (specific cancer type not specified)
- Compare: Adjuvant chemotherapy for experimental group vs similar drugs
- Pricing: Adjuvant chemotherapy for experimental group cost, discount & access